Apellis Pharmaceuticals Inc (APLS)
47.51
-0.52
(-1.08%)
USD |
NASDAQ |
Apr 18, 16:00
47.50
-0.01
(-0.02%)
After-Hours: 20:00
Apellis Pharmaceuticals Gross Profit Margin (Quarterly): 86.40% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 86.40% |
| September 30, 2023 | 79.70% |
| June 30, 2023 | 91.18% |
| March 31, 2023 | 82.59% |
| December 31, 2022 | 87.09% |
| September 30, 2022 | 93.74% |
| June 30, 2022 | 99.50% |
| Date | Value |
|---|---|
| March 31, 2022 | 91.33% |
| December 31, 2021 | 91.62% |
| September 30, 2021 | 97.36% |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 89.98% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
79.70%
Minimum
Sep 2023
99.50%
Maximum
Jun 2022
90.04%
Average
91.18%
Median
Jun 2023
Gross Profit Margin (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 88.87% |
| Blueprint Medicines Corp | 99.64% |
| Alnylam Pharmaceuticals Inc | 80.47% |
| Ionis Pharmaceuticals Inc | 99.06% |
| Madrigal Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -195.2% |
| Return on Assets | -62.02% |
| Return on Invested Capital | -145.3% |
| Profit Margin (Quarterly) | -60.51% |
| Operating Margin (Quarterly) | -57.74% |
| Return on Net Operating Assets | -184.7% |